Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H28N2O6S |
| Molecular Weight | 544.618 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C2C=CC=CC2=C(OCC)C3=C1CN(C3=O)C4=CC=C(CC(=O)NS(=O)(=O)C5=CC=CC=C5)C=C4
InChI
InChIKey=XREWXJVMYAXCJV-UHFFFAOYSA-N
InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
| Molecular Formula | C30H28N2O6S |
| Molecular Weight | 544.618 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25894216
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25894216
GW627368 is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human prostanoid TP receptor affinity. GW627368X effectively inhibits tumor survival, motility, proliferation and angiogenesis by blocking EP4-signaling. No major organ toxicity, immunosupression, behavioral change or change in blood parameters attributable to the drug was observed.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1836 |
7.0 null [pKi] | ||
Target ID: CHEMBL2069 |
6.8 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. | 2010-06-01 |
|
| Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. | 2009-11-15 |
|
| EP4 and EP2 receptor subtypes involved in colonic secretion in rat. | 2008-09 |
|
| Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. | 2008-05 |
|
| Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. | 2008 |
|
| Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. | 2007-11 |
|
| Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. | 2007-11 |
|
| GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. | 2006-06 |
|
| Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. | 2005-02 |
Sample Use Guides
Effective and safe range is 5–15 mg/kg of body weight
Route of Administration:
Oral
In human washed platelets, GW627368X (10 microM) produced 100% inhibition of U-46619 (EC100)-induced aggregation (approximate pA2 approximately 7.0). However, in rings of rabbit and piglet saphenous vein and of guinea-pig aorta GW627368X (10 microM) did not displace U-46619 E/[A] curves indicating an affinity of < 5.0 for rabbit and guinea-pig prostanoid TP receptors.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:03:01 GMT 2025
by
admin
on
Mon Mar 31 22:03:01 GMT 2025
|
| Record UNII |
A9P1ZGY0SE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5312130
Created by
admin on Mon Mar 31 22:03:01 GMT 2025 , Edited by admin on Mon Mar 31 22:03:01 GMT 2025
|
PRIMARY | |||
|
DTXSID30195993
Created by
admin on Mon Mar 31 22:03:01 GMT 2025 , Edited by admin on Mon Mar 31 22:03:01 GMT 2025
|
PRIMARY | |||
|
439288-66-1
Created by
admin on Mon Mar 31 22:03:01 GMT 2025 , Edited by admin on Mon Mar 31 22:03:01 GMT 2025
|
PRIMARY | |||
|
A9P1ZGY0SE
Created by
admin on Mon Mar 31 22:03:01 GMT 2025 , Edited by admin on Mon Mar 31 22:03:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
